BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 19001517)

  • 1. Impact of somatostatin analogs versus surgery on glucose metabolism in acromegaly: results of a 5-year observational, open, prospective study.
    Colao A; Auriemma RS; Galdiero M; Cappabianca P; Cavallo LM; Esposito F; Grasso LF; Lombardi G; Pivonello R
    J Clin Endocrinol Metab; 2009 Feb; 94(2):528-37. PubMed ID: 19001517
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-I levels, tumor shrinkage, and cardiovascular disease: a prospective study.
    Colao A; Auriemma RS; Galdiero M; Lombardi G; Pivonello R
    J Clin Endocrinol Metab; 2009 Oct; 94(10):3746-56. PubMed ID: 19622615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly.
    Colao A; Attanasio R; Pivonello R; Cappabianca P; Cavallo LM; Lasio G; Lodrini A; Lombardi G; Cozzi R
    J Clin Endocrinol Metab; 2006 Jan; 91(1):85-92. PubMed ID: 16263832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preoperative octreotide therapy and surgery in acromegaly: associations between glucose homeostasis and treatment response.
    Helseth R; Carlsen SM; Bollerslev J; Svartberg J; Øksnes M; Skeie S; Fougner SL
    Endocrine; 2016 Feb; 51(2):298-307. PubMed ID: 26179177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of tumor shrinkage after primary therapy with somatostatin analogs in acromegaly: a prospective study in 99 patients.
    Colao A; Pivonello R; Auriemma RS; Briganti F; Galdiero M; Tortora F; Caranci F; Cirillo S; Lombardi G
    J Clin Endocrinol Metab; 2006 Jun; 91(6):2112-8. PubMed ID: 16537687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicenter study. Italian Multicenter Slow Release Lanreotide Study Group.
    Giusti M; Gussoni G; Cuttica CM; Giordano G
    J Clin Endocrinol Metab; 1996 Jun; 81(6):2089-97. PubMed ID: 8964833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of gender and gonadal status on the long-term response to somatostatin analogue treatment in acromegaly.
    Colao A; Pivonello R; Cappabianca P; Briganti F; Tortora F; Auriemma RS; De Martino MC; Marzullo P; Lombardi G
    Clin Endocrinol (Oxf); 2005 Sep; 63(3):342-9. PubMed ID: 16117824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of medical therapies for acromegaly on glucose metabolism.
    Urbani C; Sardella C; Calevro A; Rossi G; Scattina I; Lombardi M; Lupi I; Manetti L; Martino E; Bogazzi F
    Eur J Endocrinol; 2013 Jul; 169(1):99-108. PubMed ID: 23660641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucose homeostasis in acromegaly: effects of long-acting somatostatin analogues treatment.
    Baldelli R; Battista C; Leonetti F; Ghiggi MR; Ribaudo MC; Paoloni A; D'Amico E; Ferretti E; Baratta R; Liuzzi A; Trischitta V; Tamburrano G
    Clin Endocrinol (Oxf); 2003 Oct; 59(4):492-9. PubMed ID: 14510913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of treating acromegaly first with surgery or somatostatin analogs on cardiomyopathy.
    Colao A; Pivonello R; Galderisi M; Cappabianca P; Auriemma RS; Galdiero M; Cavallo LM; Esposito F; Lombardi G
    J Clin Endocrinol Metab; 2008 Jul; 93(7):2639-46. PubMed ID: 18445662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucose tolerance and somatostatin analog treatment in acromegaly: a 12-month study.
    Colao A; Auriemma RS; Savastano S; Galdiero M; Grasso LF; Lombardi G; Pivonello R
    J Clin Endocrinol Metab; 2009 Aug; 94(8):2907-14. PubMed ID: 19491229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medical treatment of acromegaly: comorbidities and their reversibility by somatostatin analogs.
    Tolis G; Angelopoulos NG; Katounda E; Rombopoulos G; Kaltzidou V; Kaltsas D; Protonotariou A; Lytras A
    Neuroendocrinology; 2006; 83(3-4):249-57. PubMed ID: 17047390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glycemic profile in patients with acromegaly treated with somatostatin analogue.
    Valea A; Carsote M; Ghervan C; Georgescu C
    J Med Life; 2015; 8 Spec Issue(Spec Issue):82-6. PubMed ID: 26361517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide.
    Morange I; De Boisvilliers F; Chanson P; Lucas B; DeWailly D; Catus F; Thomas F; Jaquet P
    J Clin Endocrinol Metab; 1994 Jul; 79(1):145-51. PubMed ID: 8027218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucose homeostasis in patients with acromegaly treated with surgery or somatostatin analogues.
    Tzanela M; Vassiliadi DA; Gavalas N; Szabo A; Margelou E; Valatsou A; Vassilopoulos C
    Clin Endocrinol (Oxf); 2011 Jul; 75(1):96-102. PubMed ID: 21521267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of the long-acting somatostatin analogue Lanreotide Autogel on glucose tolerance and insulin resistance in acromegaly.
    Steffin B; Gutt B; Bidlingmaier M; Dieterle C; Oltmann F; Schopohl J
    Eur J Endocrinol; 2006 Jul; 155(1):73-8. PubMed ID: 16793952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum leptin levels in acromegalic patients before and during somatostatin analogs therapy.
    Baldelli R; Durante C; D'Amico E; Diacono F; Tamburrano G; Casanueva FF
    J Endocrinol Invest; 2003 Dec; 26(12):1219-24. PubMed ID: 15055476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor ZAC1 expression is associated with the response to somatostatin analog therapy in patients with acromegaly.
    Theodoropoulou M; Tichomirowa MA; Sievers C; Yassouridis A; Arzberger T; Hougrand O; Deprez M; Daly AF; Petrossians P; Pagotto U; Beckers A; Stalla GK
    Int J Cancer; 2009 Nov; 125(9):2122-6. PubMed ID: 19637311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison between six-year therapy with long-acting somatostatin analogs and successful surgery in acromegaly: effects on cardiovascular risk factors.
    Ronchi CL; Varca V; Beck-Peccoz P; Orsi E; Donadio F; Baccarelli A; Giavoli C; Ferrante E; Lania A; Spada A; Arosio M
    J Clin Endocrinol Metab; 2006 Jan; 91(1):121-8. PubMed ID: 16263816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly.
    Karavitaki N; Botusan I; Radian S; Coculescu M; Turner HE; Wass JA
    Clin Endocrinol (Oxf); 2005 Mar; 62(3):282-8. PubMed ID: 15730408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.